Download PDF
Semin Thromb Hemost 2012; 38(01): 47-54
DOI: 10.1055/s-0031-1300951
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13

Kent Chapman
1   Department of Haematology, Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia
,
Michael Seldon
2   Calvary Mater Hospital, Newcastle, NSW, Australia
,
Ross Richards
3   Charles Sturt University, Wagga Wagga, NSW, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
07 February 2012 (online)

   Permissions and Reprints

Abstract

Thrombotic microangiopathy (TMA) is a term used to describe a group of disorders characterized by hemolytic anemia (with prominent red blood cell fragmentation), thrombocytopenia, and thrombosis in the microvasculature. It may be used when describing patients with thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, atypical hemolytic uremic syndrome, as well as a myriad of other disorders in which the TMA may be secondary to another disease or disorder. While limited information exists as to the exact cause of microthrombosis in many TMA, recent advances have been made in the understanding of TTP and its pathophysiology. This progress can be attributed to discovery of the von Willebrand factor cleaving protease ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), whose absence in TTP has given the disorder a distinct molecular identity. The discovery of this metalloprotease has prompted a significant amount of research relating to its role in TTP as well as its general function in hemostasis. The exact mechanisms by which this metalloprotease achieves its role are slowly being understood and these now provide other avenues by which TMA may occur.

Keywords

ADAMTS-13 - thrombotic thrombocytopenic purpura - thrombotic microangiopathy - CD36 - von Willebrand factor
 

  • References

  • 1 Lichtman LA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. Williams Hematology. 7th ed. Sydney: : McGraw-Hill Medical; ; 2006
    Search in Google Scholar
  • 2 Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006; 70 (1) 16-23
    CrossrefPubMedSearch in Google Scholar
  • 3 Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005; 3 (8) 1663-1675
    CrossrefPubMedSearch in Google Scholar
  • 4 George JN. Diagnosis of thrombotic thrombocytopaenia purpura – haemolytic uraemic syndrome in adults. 2010, Available at: www.uptodate.com/contents/diagnosis-of-thrombotic-thrombo-cytopenic-purpura-hemolytic-uremic-syndromeinadults?source=search_result&search=thombotic+thombocytopaenia+purpura&selectedTitle=1%7E150 . Accessed October 12, 2010
    PubMed
  • 5 George JN. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol 2005; 3 (8) 627-632
    PubMedSearch in Google Scholar
  • 6 Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?. J Am Soc Nephrol 2007; 18 (9) 2457-2460
    CrossrefPubMedSearch in Google Scholar
  • 7 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
    CrossrefPubMedSearch in Google Scholar
  • 8 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
    CrossrefPubMedSearch in Google Scholar
  • 9 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007; 33 (8) 787-797
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2010; 36 (1) 71-81
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Favaloro EJ. Hemolytic uremic syndrome. Preface. Semin Thromb Hemost 2010; 36 (6) 573-574
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36 (6) 575-585
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Just S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost 2010; 36 (1) 82-90
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hithero undescribed disease. Proc N Y Pathol Soc. 1924; 24: 21-24
    PubMedSearch in Google Scholar
  • 15 Baehr G, Kelmerer P, Schifrin A. Acute febrile anemia and thrombocytopenic purpura with diffuse platelet thrombosis of capillaries and arterioles. Tr A Am Physicians 1936; 51: 43
    PubMedSearch in Google Scholar
  • 16 Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses. Blood 1947; 2 (6) 542-554
    PubMedSearch in Google Scholar
  • 17 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-160
    CrossrefPubMedSearch in Google Scholar
  • 18 Moake JL, Rudy CK, Troll JH , et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
    CrossrefPubMedSearch in Google Scholar
  • 19 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78 (6) 1456-1461
    CrossrefPubMedSearch in Google Scholar
  • 20 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71 (5) 1366-1374
    PubMedSearch in Google Scholar
  • 21 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (6) 1662-1666
    CrossrefPubMedSearch in Google Scholar
  • 22 Levy GG, Nichols WC, Lian EC , et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855) 488-494
    CrossrefPubMedSearch in Google Scholar
  • 23 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276 (44) 41059-41063
    CrossrefPubMedSearch in Google Scholar
  • 24 Kokame K, Matsumoto M, Soejima K , et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99 (18) 11902-11907
    CrossrefPubMedSearch in Google Scholar
  • 25 Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31 (1) 11-19
    CrossrefPubMedSearch in Google Scholar
  • 26 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
    CrossrefPubMedSearch in Google Scholar
  • 27 Sheiflinger F, Knobl P, Trattner B , et al. Non-neutralising IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102 (9) 3241-3243
    CrossrefPubMedSearch in Google Scholar
  • 28 Key N, Makris M, O’shaunessy D, Lillicrap D. . Practical Hemostasis and Thrombosis. 2nd ed. Singapore: : Wiley-Blackwell; ; 2009
    CrossrefSearch in Google Scholar
  • 29 De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113 (21) 5049-5057
    CrossrefPubMedSearch in Google Scholar
  • 30 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424
    CrossrefPubMedSearch in Google Scholar
  • 31 McGrath RT, McRae E, Smith OP, O’Donnell JS. Platelet von Willebrand factor—structure, function and biological importance. Br J Haematol 2010; 148 (6) 834-843
    CrossrefPubMedSearch in Google Scholar
  • 32 Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood 1987; 69 (5) 1531-1534
    PubMedSearch in Google Scholar
  • 33 Arya M, Anvari B, Romo GM , et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002; 99 (11) 3971-3977
    CrossrefPubMedSearch in Google Scholar
  • 34 Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009; 112 (112) S11-S14
    PubMedSearch in Google Scholar
  • 35 Uchida T, Wada H, Mizutani M , et al; Research Project on Genetics of Thrombosis. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004; 104 (7) 2081-2083
    CrossrefPubMedSearch in Google Scholar
  • 36 Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004; 103 (2) 627-629
    CrossrefPubMedSearch in Google Scholar
  • 37 Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2010; 36 (1) 71-81
    Thieme ConnectPubMedSearch in Google Scholar
  • 38 Zanardelli S, Crawley JTB, Chion CK, Lam JK, Preston RJS, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006; 281 (3) 1555-1563
    CrossrefPubMedSearch in Google Scholar
  • 39 Vomund AN, Majerus EM. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 2009; 284 (45) 30925-30932
    CrossrefPubMedSearch in Google Scholar
  • 40 Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101 (3) 946-948
    CrossrefPubMedSearch in Google Scholar
  • 41 Lippi G, Franchini M, Targher G, Poli G, Guidi GC. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement. Clin Chim Acta 2007; 381 (2) 167-170
    CrossrefPubMedSearch in Google Scholar
  • 42 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (9) 2730-2735
    CrossrefPubMedSearch in Google Scholar
  • 43 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81 (1) 8-13
    Thieme ConnectPubMedSearch in Google Scholar
  • 44 Barbot J, Costa E, Guerra M , et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001; 113 (3) 649-651
    CrossrefPubMedSearch in Google Scholar
  • 45 Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 88 (4) 816-825
    CrossrefPubMedSearch in Google Scholar
  • 46 Schultz DR, Arnold PI, Jy W , et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 1998; 103 (3) 849-857
    CrossrefPubMedSearch in Google Scholar
  • 47 Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 1994; 88 (4) 878-880
    CrossrefPubMedSearch in Google Scholar
  • 48 Rock GA, Clark WF. Mechanism of microthrombosis in HUS. Kidney Int Suppl 2009; 75 (112) S15-S16
    CrossrefPubMedSearch in Google Scholar
  • 49 Nolasco LH, Turner NA, Bernardo A , et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005; 106 (13) 4199-4209
    CrossrefPubMedSearch in Google Scholar
  • 50 Morishita K, Wakamoto S, Miyazaki T , et al. Life-threatening adverse reaction followed by thrombocytopenia after passive transfusion of fresh frozen plasma containing anti-CD36 (Naka) isoantibody. Transfusion 2005; 45: 803-806
    CrossrefPubMedSearch in Google Scholar
  • 51 Wakamoto S, Fujihara M, Urushibara N , et al. Heterogeneity of platelet responsiveness to anti-CD36 in plasma associated with adverse transfusion reactions. Vox Sang 2005; 88 (1) 41-51
    CrossrefPubMedSearch in Google Scholar
  • 52 Tomiyama Y, Kunicki TJ, Zipf TF, Ford SB, Aster RH. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood 1992; 80 (9) 2261-2268
    PubMedSearch in Google Scholar
  • 53 George JN. ADAMTS13: what it does, how it works, and why it’s important. Transfusion 2009; 49 (2) 196-198
    CrossrefPubMedSearch in Google Scholar
  • 54 Crawley JT, Lam JK, Rance JB, Mollica LR, O’Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105 (3) 1085-1093
    PubMedSearch in Google Scholar
  • 55 Feys HB, Vandeputte N, Palla R , et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8 (9) 2053-2062
    CrossrefPubMedSearch in Google Scholar